Laurus Labs shifts gears as CDMO emerges as key growth driver; Nuvama sees 24% upside

Laurus Labs' shift towards contract development and manufacturing (CDMO) is expected to drive its next phase of growth. Nuvama Institutional Equities initiated coverage with a 'Buy' rating and a 24% upside target.